CYTOMATRIX
Cytomatrix is a privately owned, Australian biotechnology and materials-based company in Melbourne with a broad platform of technology applications applicable to health sciences, materials and food industries.
View our Company Presentation here.
The polymer fibre technology developed by Cytomatrix enables the manufacture of polymers fibres (diameter 15nm - 5 μm, length from 1 μm several thousand microns) using a wide range of soluble polymers.
Their porous and fibrous morphology presents unique properties compared to nanoparticles particularly in the fields of controlled release of matrix-bound biological materials. This creates the opportunity for multiple applications from coatings, drug delivery, cosmetics and sensors. The utilisation of the short polymer fibre platform can be across biology, biomedical, chemistry and material sciences.
TECHNOLOGY
Our programs of development remained focused on enhancing the polymer delivery system whilst working on specific applications.
Following proof of concept in two major oncology targets Cytomatrix is significantly increased its commitment to fast tracking the development from pre-clinical to clinical approvals of its proprietary immuno-therapy vaccine.